Andelyn Biosciences News and Resources

Andelyn Biosciences, Inc., a contract development and manufacturing organisation (CDMO), has produced an Adeno-Associated Virus (AAV) vector to support a forthcoming Phase 1 trial initiated by Nationwide Children’s Hospital (NCH). The trial will evaluate a universal-donor CD38KO CD33CAR-NK cell therapy

Andelyn Biosciences, Inc., a cell and gene therapy CDMO, has expanded its AAV Curator Platform and License Agreement with the Broad Institute of MIT and Harvard. The agreement now includes the Stanton Lab CNS capsids, which enhance brain transduction while

Andelyn Biosciences, Inc., a contract development and manufacturing organisation (CDMO) specialising in cell and gene therapies, has been selected by Hubble Therapeutics to manufacture adeno-associated virus (AAV) for the treatment of Leber Congenital Amaurosis 16 (LCA16), a rare and severe

Andelyn Biosciences, a cell and gene therapy CDMO, has secured a License Agreement with the Broad Institute to integrate MyoAAV plasmids into its AAV Curator™ Platform. Announced on August 7, 2024, this new addition aims to improve the efficiency of

Andelyn Biosciences, Inc., a Contract Development and Manufacturing Organisation (CDMO) specializing in cell and gene therapy, has been selected by UMass Chan Medical School to utilize its suspension AAV Curator™ Platform for manufacturing clinical grade AAV9-CSA vector aimed at treating

Andelyn Biosciences, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has announced a partnership with Grace Science LLC. The collaboration aims to tech transfer and manufacture GS-100, a suspension process AAV NGLY1 gene therapy. The therapy is

Andelyn Biosciences, a cell and gene therapy contract development research organisation, has been chosen as the viral vector manufacturing partner for the Foundation for the National Institutes of Health (FNIH) in the United States. This collaboration is a part of